摘要
目的 研究原发性高血压患者血清中基质金属蛋白酶 9(MMP— 9)及其抑制剂 ,金属蛋白酶组织抑制因子 1(TIMP— 1)水平的变化和左室肥厚的关系。方法 用酶联免疫吸附法对 4 0例经治疗或未治疗的原发性高血压患者进行血清MMP— 9和TIMP— 1水平测定 ,与 2 8例健康对照组进行比较。并对高血压患者进行心脏彩色多谱勒检查 ,计算左室重量指数。结果 1、高血压组血清MMP - 9较正常对照组明显降低(2 96 38± 15 9 2 3ng ml-1、4 99 6 2± 334 80ng ml-1,P <0 0 0 1)而TIMP - 1水平较正常对照组明显升高 (35 5 99± 114 95ng ml-1、2 0 5 4 5± 38 77ng ml-1,P <0 0 0 1) ;2、高血压心肌肥厚组与无肥厚组MMP - 9无显著性差异(332 71± 186 70ng ml-1、2 82 5 9± 14 9 10ng ml-1,P >0 0 5 ) ,但TIMP - 1水平心肌肥厚组明显升高 (491 2 7±75 0 3ng ml-1,2 98 4 7± 4 2 98ng ml-1P <0 0 0 1)。结论 原发性高血压患者存在基质金属蛋白酶 - 9及其抑制剂 - 1代谢异常 ,血清TIMP - 1水平可能成为反映高血压左室肥厚的指标。
Objective To investigate the significance of serum Metrix Metalloproteinase_9(MMP_9) and tissue inhibitor Metalloproteinase_1(TIMP_1), and their relationship with left ventricular hypertrophy in essential hypertension. Methods Using ELISA, serum levels of MMP_9 and TIMP_1 were measured in 40 patients with essential hypertension and 28 healthy people. Doppler echocardiography was performed in all study subjects, left ventricular mass index was defined as index for left ventricular hypertrophy. Results 1. Serum concentration of MMP_9 was lower and serum level of TIMP_1 was higher in hypertensive patients than those in normotensive control subjects( 296.38±159.23ng.ml-1 vs 499.62±334.80ng.ml-1,355.99±114.95ng.ml-1 vs 205.45±38.77ng.ml-1;P<0.001 and P<0.05,respectively). 2.Serum MMP_9 level had no different between patients with left ventricular hypertrophy and without left ventricular hypertrophy, but serum TIMP_1 level was higher in patients with left ventricular hypertrophy (491.27±75.03ng.ml-1 vs 198.47±42.98ng.ml-1,P<0.001).Conclusions Systemic extracelluar degradation of collagen is depressed in hypertensive patients because of abnormal metabolism of MMP-9 and TIMP-1, the increase in concentration of serum TIMP-1 can reflect left ventricular hypertrophy of essential hypertension.
出处
《心脑血管病防治》
2004年第2期12-14,共3页
CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
关键词
高血压
左室肥厚
基质金属蛋白酶9
金属蛋白酶组织抑制因子1
Hypertension
Matrix Metalloproteinase-9
tissue inhibitor Metalloproteinase-1
Left ventricular hypertrophy
